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S484 P.5.b Dementia and neurological disorders – Dementia disorders (basic)
also reduced in memantine-treated media compared to control.
These data suggest that memantine may affect APP processing
and may potentially inhibit the accumulation of ﬁbrillogenic Ab
peptides.
Conclusions: Further experiments are in progress to better
understand the mechanism of memantine’s effect on secretases.
P.5.b.005 Memantine rescues cholinergic neurons from
the neurotoxic effects of b-amyloid (Ab1−42)
C. Nyakas1 °, R. Szabo´1, B. Penke2, P.G.M. Luiten3,
P.K. Banerjee4. 1Semmelweis University, Brain Physiology
Research Group, Budapest, Hungary; 2Szeged University,
Department of Medical Chemistry, Szeged, Hungary; 3University
of Groningen, Department of Molecular Neuroscience, Groningen,
Netherlands; 4Forest Research Institute, Department of
Pharmacology and Toxicology, Jersey City, USA
Background: Memantine, a moderate afﬁnity uncompetitive
NMDA receptor antagonist, is approved for the treatment of
Alzheimer’s disease (AD).
Objective(s): The mechanisms by which memantine exerts its
beneﬁcial effects in AD are under investigation. Memantine has
been shown to provide neuroprotection and improve learning and
memory in several animal models. It has also been shown that
therapeutic doses of memantine reduce the levels of amyloid
precursor protein (APP), Ab1−40 and Ab1−42 peptides in human
neuroblastoma cells and in the rat primary cortical neurons.
Methods: In this study, the neuroprotective effects of meman-
tine were determined in rats with multiple unilateral Ab1−42
lesions in the nucleus basalis magnocellularis (NBM) and parietal
neocortex. The contralateral side of the brain served for control.
Memantine (30mg/kg/day) was given orally via drinking water
starting 3 days prior to lesioning and continued for 10 postoper-
ative days. For behavioural analysis open-ﬁeld exploration, novel
object recognition (attention) and one-trial step-through passive
avoidance learning paradigms were applied starting the analysis
3 days after lesion. At the end of chronic memantine treatment
(10 days after lesion) the animals were sacriﬁced for histolog-
ical examination. The impact of amyloid peptide toxication on
cholinergic cells was measured on the density of their axons
arriving to the neocortex. Cholinergic ﬁbers were immunostained
by antibody against choline-acetyltransferase (ChAT). Activated
microglia was visualized by immunostaining against integrin aM
[CD11b]. Image analyses of the immunostained anatomical struc-
tures were carried out on a Quantimet Q-5001W computerized
imaging platform (Leica). Cholinergic ﬁber loss in the parietal
neocortex layer V and the extent of microglial activation around
the NBM and cortical lesion sites were then evaluated.
Results: Ab1−42 did not inﬂuence open-ﬁeld behaviour but
signiﬁcantly decreased attention performance in the novel object
recognition test by 60% and attenuated passive avoidance learn-
ing by 67% (both signiﬁcant at p< 0.05 level). Furthermore, it
decreased cholinergic ﬁber density in the target neocortical area
against sham-lesioned control (p< 0.005) and increased microglial
activation around the lesion areas, i.e. the increment in NBM was
69% (p< 0.01) and in the neocortex 55% (p< 0.05). Memantine
treatment signiﬁcantly attenuated the behavioural deﬁcits in at-
tention and passive avoidance learning and the performance of
memantine-treated Ab1−42-lesioned group was not different from
that of sham-lesioned control group. Memantine treatment pre-
vented the Ab1−42-induced cholinergic ﬁber loss in the neocortex
(p< 0.01) and the degree of ﬁber loss in the lesioned animals was
not different from control. In addition, memantine signiﬁcantly
attenuated microglial activation in the NBM (45%) and in the
neocortical (35%) lesion sites.
Conclusions: It is concluded from these studies that (1) pre-
and postlesion continuous treatment with memantine attenuates
Ab1−42-induced attention and learning deﬁcits and (2) provides
neuroprotection against Ab1−42 toxicity on cholinergic neurons
under the conditions studied. A putative rescuing action of me-
mantine on other neuron systems damaged by Ab1−42 as com-
pared to cholinergic one merits further studies.
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Background: Several lines of evidence suggest that in
Alzheimer’s disease (AD), the neurotoxicity caused by b-amyloid
(Ab) peptides may be related to elevated levels of glutamate
and/or overactivity of the NMDA receptors. We have earlier shown
that memantine (an NMDA receptor antagonist) improves spatial
learning in APP/PS1 transgenic mice with elevated levels of Ab40
and Ab42.
Objective(s): In the present study, we determined the extracel-
lular levels of glutamate in the hippocampus of APP/PS1 mice at
6 and 16 months of age.
Methods: Extracellular levels of glutamate were measured by in
vivo microdialysis under basal and stimulated conditions (in the
absence or presence of KCl, respectively). A separate group of
6- and 16-month old APP/PS1 mice were also tested for spatial
learning in the water maze, and their brain Ab levels, amyloid
plaque burden, microgliosis and astrogliosis were determined by
ELISA and immunocytochemistry.
Results: APP/PS1 mice exhibited impaired performance in the
water maze at 16 months but not at 6 months. Although some
plaques were present at 6 months of age, the brain levels of
Ab40, Ab42 and plaque pathology increased signiﬁcantly from 6
months to 16 months. The basal extracellular glutamate level in
the hippocampus did not change at either age in APP/PS1 mice,
but the stimulated glutamate level was slightly higher at 6 months
and signiﬁcantly lower at 16 months compared to respective age-
matched wild-type controls. Basal but not peak glutamate release
correlated with the levels of vesicular glutamate transporters. The
number of reactive microglia was elevated at 16 but not at 6
months.
Conclusions: The time course of amyloid pathology and cog-
nitive dysfunction in this APP/PS1 mouse line suggest that the
observed cognitive impairment in these mice was likely associated
